FY2025 · ended Dec 31, 2025 · Revenue $244.06M, +6775.0% YoY · Filed Mar 4, 2026
Keros Therapeutics, Inc. (KROS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $244.1 million and net income of $87.0 million. Free cash flow was $106.0 million. As of Sep 30, 2026 it held $259.5 million in cash and investments and $15.1 million in total debt.
Revenue (TTM)
$40.76M
-83.5% vs year-ago TTM
Net income (TTM)
$-61.73M
-195.8% vs year-ago TTM
Operating cash flow (TTM)
$-47.85M
-153.9% vs year-ago TTM
Free cash flow (TTM)
$-48.27M
-155.4% vs year-ago TTM
EPS (TTM)
$-2.83
-279.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
19.72M
-51.4% vs prior year
Net cash
$244.35M
as of Sep 30, 2026
Operating margin
-179.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KROS (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Lexington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1664710
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $244.1M | $3.5M | $151,000 | $0 | $20.1M |
| Operating income | $67.6M | -$210.8M | -$169.9M | -$114.8M | -$56.4M |
| Net income | $87.0M | -$187.4M | -$153.0M | -$104.7M | -$58.7M |
| Diluted EPS | $2.30 | -$5.00 | -$5.20 | -$4.15 | -$2.52 |
| Operating cash flow | $107.5M | -$160.9M | -$124.5M | -$70.1M | -$62.1M |
| Free cash flow | $106.0M | -$162.8M | -$127.0M | -$71.3M | -$63.2M |
| Total assets | $338.0M | $615.9M | $370.0M | $306.8M | $255.3M |
| Total liabilities | $34.9M | $44.3M | $37.8M | $29.4M | $12.1M |
| Stockholders' equity | $303.1M | $571.6M | $332.2M | $277.4M | $243.2M |
| Cash and investments | $287.4M | $559.9M | $331.1M | $279.0M | $230.0M |
| Total debt | $16.9M | $18.9M | $14.4M | $13.3M | $1.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 29, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 28, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Other events
|
Sep 8, 2026 | Sep 8, 2026 |
All 536 Keros Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.